The partners
Join COBIOEEIT Health
Activities
Description
Since 2016, EIT Health works at the centre of a vibrant community to connect approximately 130 world-class organisations, harnessing our combined knowledge to nurture the brightest ideas, businesses and people.This unique European ecosystem provides a space where innovation can take shape through collaboration for a healthier future.
EIT Health now has a unique position in the biomanufacturing field: EIT Health is taking part in a range of different activities all under the umbrella of its new Flagship and covering all three dimensions of the knowledge triangle to answer the main challenges in the field, in line with the European strategy. The COBIOE project is a unique opportunity for EIT Health help building a single, innovative, European biomanufacturing community. It is perfectly matching the DNA of our organisation.
Genopole
Description
Genopole, founded in 1998, is the oldest French biocluster fully dedicated to biotechnology, genomics, cell and gene therapies as applied to healthcare, synthetic biology, bioproduction for food & agriculture, cosmetics and industry. It unites innovative high-tech life sciences companies, hospital, public and private research and higher education facilities at a single site, in the south of Paris. Today, Genopole is a major actor in France’s research and a key element of its industrial landscape for biotech and genomics.
Three main strategic areas : Innovative therapeutic, computational genomics and Bioeconomy. It represents a mature and fertile campus with more than 2,600 staff members which are employed on-site by the 63 biotech companies, 21 public research labs, and 29 cutting-edge shared- access technology platforms and university training courses (University of Evry Paris-Saclay).
Genopole is renowned for its scientific excellence in biotherapies. It is home to two French pioneers in the sector: Genethon for gene therapies in rare diseases, and I-Stem for the study of human pluripotent stem cells and their use in cell therapies. Indeed, Zolgensma,
the first gene therapy to be approved for the childhood neuromuscular disease spinal muscular atrophy, was the fruit of research done at Genethon. The model developed by Genopole, that is, a biocluster uniting research, entrepreneurship, training and medicine, has shown its potential. An industrial biotherapies sector has come to be at Évry-Courcouronnes in partnership with national, European and global networks. Today, the value chain is complete, from R&D through to GMP production: initial and continuous training, academic research, technology transfer accelerator for rare and common diseases, businesses providing R&D and services, a stem cell bank under construction and a gene therapy production facility. The initial successes in clinical trials and the market arrival of the resulting therapeutic innovations for both rare and common diseases have laid a path for no less than a third revolution in medicine. Genopole and its actors are able and willing to accompany this revolution and bring answers to the challenges within it. They are helping to build a biotherapies sector.
ScanBalt BioRegion
Description
ScanBalt is an innovation network that brings together academic and industrial research, university hospitals and non-university research institutions, study centres and highly specialised suppliers in the pharmaceutical, biotechnology and medical technology sectors from different European countries and regions. ScanBalt reaches out to 3000 companies, 50 university hospitals, 60 universities within health/life science incl. 25 with a focus on medtech, 50 health care clusters and networks, 75 health care sector science parks.
ScanBalt creates value by:
– promoting innovation and business
– fostering inter-regional collaboration
– reducing barriers
– enhancing visibility
– attracting resources
CEBR
Activities
Description
CEBR is a membership-driven network of life science clusters and regional ecosystems across Europe, representing over 45 subscription members and hundreds of cluster partners across the world. Together, we represent and support a critical mass of SMEs, and hundreds of universities and research centers.
Health Cluster Portugal
Description
With more than 220 members, the Health Cluster Portugal’s mission is to contribute to greater competitiveness in the national health value chain by valuing the knowledge generated and available in universities, research institutes, hospitals and companies within a framework of economic and social development, sustainability and more and better health for all.
Its main objective is to mobilize, aggregate and catalyze the health ecosystem in order to facilitate and accelerate its development, which involves: -Inspiring the interaction between its different actors – promoting collaborative practices in the national and international context; -Identifying obstacles and opportunities – overcoming some and enhancing others by building innovative solutions, within a framework leveraged by their recognition and notoriety, seeking to contribute to greater generation of wealth, guaranteeing the sustainability of the entire system, aiming for more and better health for the citizens.
As part of its strategic agendas, the Health Cluster Portugal aims to promote the regional bioproduction ecosystem and enable its growth within a pan-European context. The COBIOE project is not only an important tool to achieve this, but also the starting point for a truly integrated European network in the field of bioproduction.